摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-tert-Butoxycarbonyl-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperidine | 333987-30-7

中文名称
——
中文别名
——
英文名称
1-tert-Butoxycarbonyl-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperidine
英文别名
tert-butyl 4-((4-(trifluoromethoxy)phenyl)sulfonyl)piperidine-1-carboxylate;tert-butyl 4-[4-(trifluoromethoxy)phenyl]sulfonylpiperidine-1-carboxylate
1-tert-Butoxycarbonyl-4-{[4-(trifluoromethoxy)phenyl]sulfonyl}piperidine化学式
CAS
333987-30-7
化学式
C17H22F3NO5S
mdl
——
分子量
409.427
InChiKey
OYAFSTIZURIYSZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    27
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    81.3
  • 氢给体数:
    0
  • 氢受体数:
    8

文献信息

  • [EN] ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'ARYLCARBOXAMIDE COMME BLOQUEURS DE TTX-S
    申请人:RAQUALIA PHARMA INC
    公开号:WO2011058766A1
    公开(公告)日:2011-05-19
    The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar1 is phenyl; Ar2 is aryl; n is 1-4; X is -O-, -S-, -SO- or -SO2-, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.
    本发明涉及式(I)的芳基羧酰胺衍生物,其中Ar1为苯基;Ar2为芳基;n为1-4;X为-O-、-S-、-SO-或-SO2-,其前体药物或其药学上可接受的盐,具有作为TTX-S通道的电压门控通道的阻塞活性,并且在治疗或预防涉及电压门控通道的疾病和疾病中如疼痛等方面具有用途。该发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及电压门控通道的疾病如疼痛中的用途。
  • [EN] CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS<br/>[FR] COMPOSES D'AMINE CYCLIQUE UTILISES COMME ANTAGONISTES DE CCR5
    申请人:TAKEDA CHEMICAL INDUSTRIES LTD
    公开号:WO2001025200A1
    公开(公告)日:2001-04-12
    A compound of formula (I) (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R?1 and R2¿ may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N?+-R5 •Y-(R5¿ is a hydrocarbon group; Y- is a counter anion); R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G1 is a bond, CO or SO¿2; G?2 is CO, SO¿2?, NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G?1¿ is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物式为(I)(其中R1是氢原子,可被取代的碳氢基团,可被取代的非芳香杂环基团,R2是可被取代的碳氢基团,可被取代的非芳香杂环基团,或R1和R2可以与A一起结合形成可被取代的杂环基团;A是N或N+ -R5 • Y-(R5是碳氢基团;Y-是反离子);R3是可被取代的环烃基团或可被取代的杂环基团;n为0或1;R4是氢原子,可被取代的碳氢基团,可被取代的杂环基团,可被取代的烷氧基,可被取代的芳氧基,或可被取代的基,E是可被除氧基以外的基取代的二价脂肪烃基团;G1是键,CO或SO2;G2是CO,SO2,NHCO,CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是一个键或一个可被取代的二价C1-3脂肪基团;前提是当G2是OCO时,J是甲基,当另一个是键时,其中一个不是键,当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,并可用于人类各种HIV感染疾病(例如艾滋病)的治疗或预防。
  • Cyclic amine compounds as CCR5 antagonists
    申请人:——
    公开号:US20030114443A1
    公开(公告)日:2003-06-19
    A compound of formula (I) (wherein R 1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R 2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R 1 and R 2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N + —R 5 .Y − (R 5 is a hydrocarbon group; Y − is a counter anion); R 3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R 4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group(s) other than oxo; G 1 is a bond, CO or SO 2 ; G 2 is CO, SO 2 , NHCO, CONH or OCO; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C 1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G 2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group(s) when G 1 is a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in human (e.g. AIDS).
    化合物的式子 (I) (其中R1是氢原子、可以被取代的碳氢基团、可以被取代的非芳香族杂环基团,R2是可以被取代的碳氢基团、可以被取代的非芳香族杂环基团,或R1和R2可以与A结合形成可以被取代的杂环基团;A是N或N+—R5.Y−(R5是碳氢基团;Y−是反离子);R3是可以被取代的环烃基团或可以被取代的杂环基团;n为0或1;R4是氢原子、可以被取代的碳氢基团、可以被取代的杂环基团、可以被取代的烷氧基、可以被取代的芳氧基,或可以被取代的基团;E是可以被取代的二价脂肪烃基团,该基团可以被除氧基团外的其他基团取代;G1是键、CO或SO2;G2是CO、SO2、NHCO、CONH或OCO;J是甲基或氮原子;Q和R中的每一个都是键或可以被取代的二价C1-3脂肪基团;但是当G2是OCO时,J是甲基;当Q和R中的一个是键时,另一个不是键;当G1是键时,Q和R中的每一个都没有被氧基团取代)或其盐具有强效的CCR5拮抗活性,可以用于治疗或预防人类各种HIV感染性疾病(例如艾滋病)。
  • ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
    申请人:Yamagishi Tatsuya
    公开号:US20120232052A1
    公开(公告)日:2012-09-13
    The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.
    本发明涉及公式(I)的芳基羧酰胺衍生物,其中Ar1是苯基;Ar2是芳基;n为1-4;X为—O—、—S—、—SO—或—SO2—,其前体药物或其药学上可接受的盐,具有阻断电压门控通道如TTX-S通道的活性,并在治疗或预防涉及电压门控通道的疾病和疾病,如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控通道的疾病和疾病,如疼痛方面的使用。
  • Cyclic Amine Compounds as CCR5 Antagonists
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1886994A1
    公开(公告)日:2008-02-13
    A compound of the formula: (wherein R1 is a hydrogen atom, a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, R2 is a hydrocarbon group which may be substituted, a non-aromatic heterocyclic group which may be substituted, or R1 and R2 may combine to each other together with A to form a heterocyclic group which may be substituted; A is N or N+-R5 . Y- (R5 is a hydrocarbon group; Y- is a counter anion) ; R3 is a cyclic hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; n is 0 or 1; R4 is a hydrogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, an alkoxy group which may be substituted, an aryloxy group which may be substituted, or an amino group which may be substituted, E is a divalent aliphatic hydrocarbon group which may be substituted by group (s) other than oxo;G1 is a bond, CO or SO2 ; G2 is CO,S02, NHCO, CONH or OCO ; J is methine or a nitrogen atom; and each of Q and R is a bond or a divalent C1-3 aliphatic hydrocarbon which may be substituted; provided that J is methine when G2 is OCO, that one of Q and R is not a bond when the other is a bond and that each of Q and R is not substituted by oxo group (s) whenGo ils a bond) or a salt thereof has a potent CCR5 antagonistic activity and can be advantageously used for the treatment or prevention of infectious disease of various HIV in humans (e.g. AIDS).
    式中的化合物: (其中 R1 是氢原子、可被取代的烃基、可被取代的非芳香杂环基团,R2 是可被取代的烃基、可被取代的非芳香杂环基团,或 R1 和 R2 可与 A 相互结合形成可被取代的杂环基团;A 是 N 或 N+-R5 .Y-(R5 是烃基;Y- 是反阴离子);R3 是可被取代的环烃基或可被取代的杂环基;n 是 0 或 1;R4 是氢原子、可被取代的烃基、可被取代的杂环基、可被取代的烷氧基、可被取代的芳氧基或可被取代的基;E 是可被除氧代以外的基团(s)取代的二价脂肪族烃基;G1 是键、CO 或 SO2;G2 是 CO、S02、NHCO、CONH 或 OCO;J 是甲烷或氮原子;Q 和 R 各自是键或可被取代的二价 C1-3 脂肪族烃;条件是:当 G2 为 OCO 时,J 为甲烷;当另一个为键时,Q 和 R 中的一个不是键;当 Go ils 为键时,Q 和 R 中的每一个没有被氧化基团(s)取代)或其盐具有强效的 CCR5 拮抗活性,可有利地用于治疗或预防人类各种 HIV 感染性疾病(如艾滋病)。例如艾滋病)。
查看更多

同类化合物

(R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 ((3S,4R)-3-氨基-4-羟基哌啶-1-基)(2-(1-(环丙基甲基)-1H-吲哚-2-基)-7-甲氧基-1-甲基-1H-苯并[d]咪唑-5-基)甲酮盐酸盐 高氯酸哌啶 高托品酮肟 马来酸帕罗西汀 颜料红48:4 顺式3-氟哌啶-4-醇盐酸盐 顺式2,6-二甲基哌啶-4-酮 顺式1-苄基-4-甲基-3-甲氨基-哌啶 顺式-叔丁基4-羟基-3-甲基哌啶-1-羧酸酯 顺式-6-甲基-哌啶-1,3-二甲酸1-叔丁酯 顺式-5-(三氟甲基)哌啶-3-羧酸甲酯盐酸盐 顺式-4-叔丁基-2-甲基哌啶 顺式-4-Boc-氨基哌啶-3-甲酸甲酯 顺式-4-(氮杂环丁烷-1-基)-3-氟哌 顺式-3-顺式-4-氨基哌啶 顺式-3-甲氧基-4-氨基哌啶 顺式-3-BOC-3,7-二氮杂双环[4.2.0]辛烷 顺式-3-(1-吡咯烷基)环丁腈 顺式-3,5-哌啶二羧酸 顺式-3,4-二溴-3-甲基吡咯烷盐酸盐 顺式-2,6-二甲基-4-氧代哌啶-1-羧酸叔丁基酯 顺式-1-叔丁氧羰基-4-甲基氨基-3-羟基哌啶 顺式-1-boc-3,4-二氨基哌啶 顺式-1-(4-叔丁基环己基)-4-苯基-4-哌啶腈 顺式-1,3-二甲基-4-乙炔基-6-苯基-3,4-哌啶二醇 顺-4-(4-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-4-(2-氟苯基)-1-(4-异丙基环己基)-4-哌啶羧酸 顺-3-氨基-4-氟哌啶-1-羧酸叔丁酯 顺-1-苄基-4-甲基哌啶-3-氨基酸甲酯盐酸盐 非莫西汀 雷芬那辛 雷拉地尔 阿维巴坦中间体4 阿格列汀杂质 阿尼利定盐酸盐 CII 阿尼利定 阿塔匹酮 阿哌沙班杂质BMS-591455 阿哌沙班杂质87 阿哌沙班杂质52 阿哌沙班杂质51 阿哌沙班杂质5 阿哌沙班杂质 阿哌沙班杂质 阿哌沙班-d3 阿哌沙班 阻聚剂701 间氨基谷氨酰胺